Search

Your search keyword '"DACARBAZINE"' showing total 171 results

Search Constraints

Start Over You searched for: Descriptor "DACARBAZINE" Remove constraint Descriptor: "DACARBAZINE" Publication Type Electronic Resources Remove constraint Publication Type: Electronic Resources
171 results on '"DACARBAZINE"'

Search Results

1. The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients : A case series and meta-analysis

2. Study of the photodegradation and photostability of anti-cancer drugs in different media towards the development of both new actinometers and liquid formulations

3. Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial.

4. Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.

5. Does local drug delivery still hold therapeutic promise for brain cancer? A systematic review.

6. Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas.

7. Synthesis, Spectroscopic, and Theoretical Study of Copper and Cobalt Complexes with Dacarbazine

8. Synthesis, Spectroscopic, and Theoretical Study of Copper and Cobalt Complexes with Dacarbazine

9. Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials.

10. Pimasertib Versus Dacarbazine in Patients With UnresectableNRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover

11. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

12. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.

13. Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201).

14. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first‐line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

15. Comorbidity assessment to determine prognosis in older adult patients with classical Hodgkin lymphoma

16. Pimasertib versus dacarbazine in patients with unresectable NRAS-mutated cutaneous melanoma: Phase II, randomized, controlled trial with crossover

17. A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma

18. Irradiated blood product use in patients at risk for transfusion-associated graft-versus-host disease.

19. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

20. A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma.

21. Zika virus has oncolytic activity against glioblastoma stem cells.

22. Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.

23. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.

24. Association of early changes in 1H MRSI parameters with survival for patients with newly diagnosed glioblastoma receiving a multimodality treatment regimen.

25. Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813.

26. Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results.

27. High frequency of brain metastases after adjuvant therapy for high-risk melanoma.

28. Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study.

29. Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas.

30. Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature.

31. Short course radiotherapy concomitant with temozolomide in GBM patients: A phase II study

32. A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation

33. Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma

34. Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: A single institution phase II study

35. Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525.

36. KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment.

37. The effects of sequential treatments on hippocampal volumes in malignant glioma patients.

38. MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival.

39. Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation.

40. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.

41. Vemurafenib in patients with BRAF(V600) mutation-positive meta-static melanoma: final overall survival results of the BRIM-3 study

42. Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma

43. Infrared spectra of primary melanomas can predict response to chemotherapy: The example of dacarbazine

44. Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma.

45. Antitumor activity of a polypyridyl chelating ligand: in vitro and in vivo inhibition of glioma.

46. Chemotherapeutic effect of a novel temozolomide analog on nasopharyngeal carcinoma in vitro and in vivo.

47. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.

49. Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.

50. Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era.

Catalog

Books, media, physical & digital resources